Published in J Virol on October 29, 2008
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2010) 1.12
Aquareovirus effects syncytiogenesis by using a novel member of the FAST protein family translated from a noncanonical translation start site. J Virol (2009) 0.93
Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res (2013) 0.91
Facilitated leaky scanning and atypical ribosome shunting direct downstream translation initiation on the tricistronic S1 mRNA of avian reovirus. Nucleic Acids Res (2010) 0.87
Multifaceted sequence-dependent and -independent roles for reovirus FAST protein cytoplasmic tails in fusion pore formation and syncytiogenesis. J Virol (2009) 0.85
Polybasic trafficking signal mediates golgi export, ER retention or ER export and retrieval based on membrane-proximity. PLoS One (2014) 0.84
Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy. Mol Ther (2014) 0.83
Helix-destabilizing, beta-branched, and polar residues in the baboon reovirus p15 transmembrane domain influence the modularity of FAST proteins. J Virol (2011) 0.82
Entirely plasmid-based reverse genetics system for rotaviruses. Proc Natl Acad Sci U S A (2017) 0.81
Discovery of an orthoreovirus in the aborted fetus of a Steller sea lion (Eumetopias jubatus). J Gen Virol (2011) 0.81
A compact, multifunctional fusion module directs cholesterol-dependent homomultimerization and syncytiogenic efficiency of reovirus p10 FAST proteins. PLoS Pathog (2014) 0.81
Lysophosphatidylcholine reversibly arrests pore expansion during syncytium formation mediated by diverse viral fusogens. J Virol (2014) 0.81
Glutamatergic synaptic integration of locomotion speed via septoentorhinal projections. Nat Neurosci (2016) 0.80
Efficient reovirus- and measles virus-mediated pore expansion during syncytium formation is dependent on annexin A1 and intracellular calcium. J Virol (2014) 0.78
Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Virology (2014) 0.77
An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells. Virology (2015) 0.77
A Bat-Derived Putative Cross-Family Recombinant Coronavirus with a Reovirus Gene. PLoS Pathog (2016) 0.77
Using targeted virotherapy to treat a resistant Ewing sarcoma model: from the bedside to the bench and back. ScientificWorldJournal (2014) 0.76
Oncolytic viruses: now interviewing for the all-star game. Mol Ther (2010) 0.75
Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. Viruses (2017) 0.75
Reovirus FAST Proteins Drive Pore Formation and Syncytiogenesis Using a Novel Helix-Loop-Helix Fusion-Inducing Lipid Packing Sensor. PLoS Pathog (2015) 0.75
Polio, still lurking in the shadows. J Neurosci (2013) 0.75
Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer. Cancer Gene Ther (2016) 0.75
Whole-Genome Analysis of a Novel Fish Reovirus (MsReV) Discloses Aquareovirus Genomic Structure Relationship with Host in Saline Environments. Viruses (2015) 0.75
Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models. Mol Ther Oncolytics (2017) 0.75
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Budding of rabies virus particles in the absence of the spike glycoprotein. Cell (1996) 4.46
Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell (1997) 3.46
Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol (1998) 3.07
VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell (2005) 2.55
Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med (2004) 2.42
Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell (2000) 2.33
The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J Virol (2000) 1.96
A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses. EMBO J (2000) 1.66
Avian reovirus: structure and biology. Virus Res (2006) 1.59
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology (2004) 1.53
Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis. Brain Res (1994) 1.43
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther (2005) 1.43
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res (2002) 1.42
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst (2006) 1.36
Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell-cell fusion. J Virol (2004) 1.32
Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability. J Virol (2005) 1.22
The S4 genome segment of baboon reovirus is bicistronic and encodes a novel fusion-associated small transmembrane protein. J Virol (2002) 1.15
Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med (2007) 1.14
Structure and cytopathic effects of Nelson Bay virus. J Virol (1970) 1.11
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
Characterization of two avian reoviruses that exhibit strain-specific quantitative differences in their syncytium-inducing and pathogenic capabilities. Virology (1998) 1.07
Outbreak of Orthoreovirus-induced meningoencephalomyelitis in baboons. Comp Med (2000) 1.06
Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol (2007) 1.06
Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent. J Immunol (2007) 1.04
Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther (2004) 1.03
A virus-encoded cell-cell fusion machine dependent on surrogate adhesins. PLoS Pathog (2008) 1.01
Characterization of a reovirus isolate from a rattle snake, Crotalus viridis, with neurological dysfunction. Arch Virol (1994) 0.96
Characterization of a novel syncytium-inducing baboon reovirus. Virology (1995) 0.96
Isolation and experimental transmission of a reovirus pathogenic in ratsnakes (Elaphe species). Virus Res (1999) 0.92
Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors. Int J Mol Med (2007) 0.84
The soluble viral glycoprotein of vesicular stomatitis virus efficiently sensitizes target cells for lysis by CD4+ T lymphocytes. J Virol (1990) 0.82
A comparison of the pathogenicity of four avian reoviruses in chickens. Avian Dis (1987) 0.81
An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell (2003) 15.12
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer (2005) 3.93
Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol (2004) 2.68
Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med (2004) 2.42
Translational control of the innate immune response through IRF-7. Nature (2008) 2.30
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol (2006) 2.16
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 2.14
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Suppression of PKR promotes network excitability and enhanced cognition by interferon-γ-mediated disinhibition. Cell (2011) 1.89
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73
Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab (2007) 1.71
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 1.60
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res (2013) 1.55
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res (2009) 1.53
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Structure of avian orthoreovirus virion by electron cryomicroscopy and image reconstruction. Virology (2005) 1.47
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A (2010) 1.39
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther (2011) 1.39
Cigarette smoke impacts immune inflammatory responses to influenza in mice. Am J Respir Crit Care Med (2006) 1.38
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther (2010) 1.38
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst (2006) 1.36
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther (2004) 1.35
Targeting tumor vasculature with an oncolytic virus. Mol Ther (2011) 1.35
Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell-cell fusion. J Virol (2004) 1.32
Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol (2007) 1.26
Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther (2007) 1.22
Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability. J Virol (2005) 1.22
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther (2010) 1.22
Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol Genet Metab (2010) 1.17
Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR. J Virol (2004) 1.15
The S4 genome segment of baboon reovirus is bicistronic and encodes a novel fusion-associated small transmembrane protein. J Virol (2002) 1.15
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med (2013) 1.13
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther (2013) 1.13
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2010) 1.12
Sequential partially overlapping gene arrangement in the tricistronic S1 genome segments of avian reovirus and Nelson Bay reovirus: implications for translation initiation. J Virol (2002) 1.10
Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res (2012) 1.09
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol (2009) 1.06
Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by sequential permeabilization of the cell membrane and targeting of mitochondria. Exp Cell Res (2007) 1.06
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res (2008) 1.06
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev (2010) 1.06
Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol Res (2013) 1.05
Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther (2010) 1.05
Membrane perturbation elicits an IRF3-dependent, interferon-independent antiviral response. J Virol (2011) 1.05
Palmitoylation, membrane-proximal basic residues, and transmembrane glycine residues in the reovirus p10 protein are essential for syncytium formation. J Virol (2003) 1.04
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther (2012) 1.03
Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther (2009) 1.03
Liposome reconstitution of a minimal protein-mediated membrane fusion machine. EMBO J (2005) 1.02
Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) (2006) 1.02
Leaky scanning and scanning-independent ribosome migration on the tricistronic S1 mRNA of avian reovirus. J Biol Chem (2007) 1.02
Internal translation initiation mediated by the angiogenic factor Tie2. J Biol Chem (2005) 1.01
A virus-encoded cell-cell fusion machine dependent on surrogate adhesins. PLoS Pathog (2008) 1.01
Myristoylation, a protruding loop, and structural plasticity are essential features of a nonenveloped virus fusion peptide motif. J Biol Chem (2004) 1.00
Structural and functional properties of an unusual internal fusion peptide in a nonenveloped virus membrane fusion protein. J Virol (2004) 1.00
Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther (2009) 1.00
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Curr Pharm Biotechnol (2012) 1.00
Bioinformatics of recent aqua- and orthoreovirus isolates from fish: evolutionary gain or loss of FAST and fiber proteins and taxonomic implications. PLoS One (2013) 1.00
Cigarette smoke suppresses type I interferon-mediated antiviral immunity in lung fibroblast and epithelial cells. J Interferon Cytokine Res (2008) 0.99
Unusual topological arrangement of structural motifs in the baboon reovirus fusion-associated small transmembrane protein. J Virol (2005) 0.99
Piscine reovirus encodes a cytotoxic, non-fusogenic, integral membrane protein and previously unrecognized virion outer-capsid proteins. J Gen Virol (2013) 0.99
Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review. Cancer Genet Cytogenet (2008) 0.99
Internal ribosome entry site-mediated translation of Apaf-1, but not XIAP, is regulated during UV-induced cell death. J Biol Chem (2006) 0.98
CHD1 associates with NCoR and histone deacetylase as well as with RNA splicing proteins. Biochem Biophys Res Commun (2003) 0.98
Virion structure of baboon reovirus, a fusogenic orthoreovirus that lacks an adhesion fiber. J Virol (2011) 0.98
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther (2008) 0.98
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res (2006) 0.98
Strategies to enhance viral penetration of solid tumors. Hum Gene Ther (2011) 0.97
Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun (2013) 0.97
IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res (2011) 0.97
Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One (2010) 0.97
FimH can directly activate human and murine natural killer cells via TLR4. Mol Ther (2010) 0.97
Chromosomal position effects are linked to sir2-mediated variation in transcriptional burst size. Biophys J (2011) 0.97
Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Mol Ther (2008) 0.96
Matrix protein mediated shutdown of host cell metabolism limits vesicular stomatitis virus-induced interferon-alpha responses to plasmacytoid dendritic cells. Immunobiology (2007) 0.96
Sequences of avian reovirus M1, M2 and M3 genes and predicted structure/function of the encoded mu proteins. Virus Res (2005) 0.96